Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Molly Harper Sells 17,500 Shares

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Molly Harper sold 17,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total value of $385,000.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Catalyst Pharmaceuticals Price Performance

Catalyst Pharmaceuticals stock opened at $22.07 on Friday. Catalyst Pharmaceuticals, Inc. has a 1-year low of $13.00 and a 1-year high of $24.27. The company’s 50-day moving average is $21.26 and its 200 day moving average is $18.76. The firm has a market capitalization of $2.63 billion, a P/E ratio of 18.70, a price-to-earnings-growth ratio of 3.44 and a beta of 0.75.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in Catalyst Pharmaceuticals by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock worth $127,212,000 after purchasing an additional 860,244 shares during the period. American International Group Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 10.0% in the first quarter. American International Group Inc. now owns 60,087 shares of the biopharmaceutical company’s stock valued at $958,000 after acquiring an additional 5,463 shares in the last quarter. Lazard Asset Management LLC lifted its stake in Catalyst Pharmaceuticals by 36.6% in the first quarter. Lazard Asset Management LLC now owns 30,334 shares of the biopharmaceutical company’s stock worth $482,000 after acquiring an additional 8,133 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Catalyst Pharmaceuticals by 1.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,219,418 shares of the biopharmaceutical company’s stock worth $19,439,000 after acquiring an additional 22,860 shares in the last quarter. Finally, California State Teachers Retirement System increased its position in Catalyst Pharmaceuticals by 4.3% during the 1st quarter. California State Teachers Retirement System now owns 106,357 shares of the biopharmaceutical company’s stock valued at $1,695,000 after purchasing an additional 4,346 shares during the period. 79.22% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on CPRX. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Truist Financial boosted their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Citigroup upped their target price on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, Stephens initiated coverage on shares of Catalyst Pharmaceuticals in a report on Monday, November 18th. They issued an “overweight” rating and a $35.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $31.14.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.